Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM). Issue 4 (July 2019)

• Record Type: Journal Article
• Authors: Giuseppa Vitale, Maria; Bracarda, Sergio; Cosmai, Laura; Crocetti, Emanuele; Di Lorenzo, Giuseppe; Lapini, Alberto; Mandressi, Alberto; Martorana, Giuseppe; Masini, Cristina; Montironi, Rodolfo; Ortega, Cinzia; Passalacqua, Rodolfo; Porta, Camillo; Procopio, Giuseppe; Sepe, Pierangela; Romano, Luigia; Luigi Pappagallo, Giovanni; Conti, Giario; Guida, Michele; Martignoni, Guido; Nolè, Franco; Pignata, Sandro; Gori, Stefania; Cartenì, Giacomo
• Is Part Of: Tumori. Volume 105:Issue 4(2019)Supplement
• Page Start: 3
• Page End: 12
• Publication Date: 2019-07
• Subjects: AIOM -- Italian -- renal cell cancer -- guidelines -- recommendation; Cancer -- Periodicals; 616.994
• DOI: 10.1177/0300891619853392
• Languages: English
• ISSNs: 0300-8916

Abstract

In the past two decades, the treatment landscape for patients with metastatic renal cell carcinoma has significantly changed thanks to the approval of several targeted molecular therapies (VEGF and mTOR inhibitors) and recently immune-checkpoint inhibitors. The Italian Association of Medical Oncology (AIOM) Renal Cell Cancer (RCC) Guidelines Panel has developed clinical guidelines to provide evidence-based information and recommendations to oncologists, urologists and all professionals involved in the management of patients with renal cell cancer.